Medical conditions with neuropsychiatric manifestations

Medical Clinics of North America

Volumn 98, Issue 5, 2014, Pages 1193-1208

  Isaac, Margaret L ^a   Larson, Eric B ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmune inflammatory disease; Central nervous system (CNS); Cognitive impairment; Dementia; Mood disorders; Neuropsychiatric symptoms; Peripheral nervous system

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CALCIUM; CEFOTAXIME; CEFTRIAXONE; COBALAMIN; CYCLOPHOSPHAMIDE; DOXYCYCLINE; PENICILLIN G; PROCAINE PENICILLIN;

ADDISON DISEASE; AUTOIMMUNE DISEASE; COGNITIVE DEFECT; CRYPTOCOCCAL MENINGITIS; CUSHING SYNDROME; CYTOMEGALOVIRUS INFECTION; ENDOCRINE DISEASE; GENETIC DISORDER; HEMATOLOGIC DISEASE; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCALCEMIA; HYPOCALCEMIA; LYME DISEASE; MENTAL DISEASE; METABOLIC DISORDER; NEUROLOGIC DISEASE; NEUROPSYCHIATRY; NEUROSYPHILIS; PARANEOPLASTIC NEUROPATHY; PARANEOPLASTIC SYNDROME; PHYSICAL EXAMINATION; PORPHYRIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; SARCOIDOSIS; SYMPTOM; SYPHILIS; THYROID DISEASE; TOXOPLASMOSIS; WILSON DISEASE;

AUTOIMMUNE/INFLAMMATORY DISEASE; CENTRAL NERVOUS SYSTEM (CNS); COGNITIVE IMPAIRMENT; DEMENTIA; MOOD DISORDERS; NEUROPSYCHIATRIC SYMPTOMS; PERIPHERAL NERVOUS SYSTEM;

ADRENAL INSUFFICIENCY; ANTIVIRAL AGENTS; AVITAMINOSIS; COGNITION DISORDERS; CUSHING SYNDROME; ENCEPHALITIS, VIRAL; HEPATOLENTICULAR DEGENERATION; HIV INFECTIONS; HUMANS; HYPERCALCEMIA; HYPOCALCEMIA; IMMUNOCOMPROMISED HOST; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYME DISEASE; MENINGITIS, CRYPTOCOCCAL; NERVOUS SYSTEM DISEASES; NEUROPSYCHOLOGICAL TESTS; NEUROSYPHILIS; PARANEOPLASTIC SYNDROMES; PORPHYRIAS; SARCOIDOSIS; THYROID DISEASES; TOXOPLASMOSIS;

EID: 84906054542     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2014.06.012     Document Type: Review

References (84)

1. Janssen R.S., Cornblath D.R., Epstein L.G., et al. Human immunodeficiency virus (HIV) infection and the nervous system: report from the American Academy of Neurology AIDS Task Force. Neurology 1989, 39(1):119-122.
2. Grassi B., Garghentini G., Gambini O., et al. Neuropsychiatric aspects of HIV infection: a liaison psychiatry study. Eur Psychiatry 1997, 12(1):16-20.
3. Gisslén M., Price R.W., Nilsson S. The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence?. BMC Infect Dis 2011, 11:356.
4. Heaton R.K., Franklin D.R., Ellis R.J., et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. JNeurovirol 2011, 17(1):3-16.
5. Crum-Cianflone N.F., Moore D.J., Letendre S., et al. Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons. Neurology 2013, 80(4):371-379.
6. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a working group of the American Academy of Neurology AIDS Task Force. Neurology 1991, 41(6):778-785.
7. McDaniel J.S., Purcell D.W., Farber E.W. Severe mental illness and HIV-related medical and neuropsychiatric sequelae. Clin Psychol Rev 1997, 17(3):311-325.
8. Power C., Gladden J.G., Halliday W., et al. AIDS- and non-AIDS-related PML association with distinct p53 polymorphism. Neurology 2000, 54(3):743-746.
9. Tan C.S., Koralnik I.J. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010, 9(4):425-437.
10. Bernal-Cano F., Joseph J.T., Koralnik I.J. Spinal cord lesions of progressive multifocal leukoencephalopathy in an acquired immunodeficiency syndrome patient. JNeurovirol 2007, 13(5):474-476.
11. Engsig F.N., Hansen A.B., Omland L.H., et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. JInfect Dis 2009, 199(1):77-83.
12. Hall C.D., Dafni U., Simpson D., et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. NEngl J Med 1998, 338(19):1345-1351.
13. Kaplan J.E., Benson C., Holmes K.K., et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009, 58(RR-4):1-207. [quiz: CE1-4].
14. Pirskanen-Matell R., Grützmeier S., Nennesmo I., et al. Impairment of short-term memory and Korsakoff syndrome are common in AIDS patients with cytomegalovirus encephalitis. Eur J Neurol 2009, 16(1):48-53.
15. Arribas J.R., Clifford D.B., Fichtenbaum C.J., et al. Level of cytomegalovirus (CMV) DNA in cerebrospinal fluid of subjects with AIDS and CMV infection of the central nervous system. JInfect Dis 1995, 172(2):527-531.
16. Mussini C., Mongiardo N., Manicardi G., et al. Relevance of clinical and laboratory findings in the diagnosis of cytomegalovirus encephalitis in patients with AIDS. Eur J Clin Microbiol Infect Dis 1997, 16(6):437-444.
17. Whitley R.J., Jacobson M.A., Friedberg D.N., et al. Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA. Arch Intern Med 1998, 158(9):957-969.
18. Anduze-Faris B.M., Fillet A.M., Gozlan J., et al. Induction and maintenance therapy of cytomegalovirus central nervous system infection in HIV-infected patients. AIDS 2000, 14(5):517-524.
19. Cohen B.A. Prognosis and response to therapy of cytomegalovirus encephalitis and meningomyelitis in AIDS. Neurology 1996, 46(2):444-450.
20. Fauci A.S., Isselbacher K.J., Wilson J.D., et al. Harrison's principles of internal medicine 1998, McGraw-Hill, New York. 14th edition.
21. Read P.J., Donovan B. Clinical aspects of adult syphilis. Intern Med J 2012, 42(6):614-620.
22. Mattei P.L., Beachkofsky T.M., Gilson R.T., et al. Syphilis: a reemerging infection. Am Fam Physician 2012, 86(5):433-440.
23. Workowski K.A., Berman S., Centers for Disease Control and Prevention (CDC) Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010, 59(RR-12):1-110.
24. Wormser G.P., Halperin J.J. Toward a better understanding of European Lyme neuroborreliosis. Clin Infect Dis 2013, 57(4):510-512.
25. Dattwyler R.J., Luft B.J. Overview of the clinical manifestations of Borrelia burgdorferi infection. Can J Infect Dis 1991, 2(2):61-63.
26. Halperin J., Luft B.J., Volkman D.J., et al. Lyme neuroborreliosis. Peripheral nervous system manifestations. Brain 1990, 113(Pt 4):1207-1221.
27. Lakos A. CSF findings in Lyme meningitis. JInfect 1992, 25(2):155-161.
28. Wormser G.P., Dattwyler R.J., Shapiro E.D., et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006, 43(9):1089-1134.
29. Jennekens F.G., Kater L. The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: a literature investigation. Rheumatology (Oxford) 2002, 41(6):605-618.
30. Ward M.M., Studenski S. The time course of acute psychiatric episodes in systemic lupus erythematosus. JRheumatol 1991, 18(4):535-539.
31. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40(9):1725.
32. Tan E.M., Cohen A.S., Fries J.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25(11):1271-1277.
33. Petri M., Orbai A.M., Alarcón G.S., et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012, 64(8):2677-2686.
34. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999, 42(4):599-608.
35. Hanly J.G. ACR classification criteria for systemic lupus erythematosus: limitations and revisions to neuropsychiatric variables. Lupus 2004, 13(11):861-864.
36. Efthimiou P., Blanco M. Pathogenesis of neuropsychiatric systemic lupus erythematosus and potential biomarkers. Mod Rheumatol 2009, 19(5):457-468.
37. Conti F., Alessandri C., Bompane D., et al. Autoantibody profile in systemic lupus erythematosus with psychiatric manifestations: a role for anti-endothelial-cell antibodies. Arthritis Res Ther 2004, 6(4):R366-R372.
38. Denburg J.A., Behmann S.A. Lymphocyte and neuronal antigens in neuropsychiatric lupus: presence of an elutable, immunoprecipitable lymphocyte/neuronal 52 kd reactivity. Ann Rheum Dis 1994, 53(5):304-308.
39. Burns T.M. Neurosarcoidosis. Arch Neurol 2003, 60(8):1166-1168.
40. Krumholz A., Stern B.J. Neurologic manifestations of sarcoidosis. Handb Clin Neurol 2014, 119:305-333.
41. Rybicki B.A., Popovich J., Maliarik M.J., et al. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 1997, 145(3):234-241.
42. Hoitsma E., Drent M., Sharma O.P. Apragmatic approach to diagnosing and treating neurosarcoidosis in the 21st century. Curr Opin Pulm Med 2010, 16(5):472-479.
43. Hoitsma E., Marziniak M., Faber C.G., et al. Small fibre neuropathy in sarcoidosis. Lancet 2002, 359(9323):2085-2086.
44. Bihan H., Christozova V., Dumas J.L., et al. Sarcoidosis: clinical, hormonal, and magnetic resonance imaging (MRI) manifestations of hypothalamic-pituitary disease in 9 patients and review of the literature. Medicine (Baltimore) 2007, 86(5):259-268.
45. Cahill D.W., Salcman M. Neurosarcoidosis: a review of the rarer manifestations. Surg Neurol 1981, 15(3):204-211.
46. Elfferich M.D., Nelemans P.J., Ponds R.W., et al. Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-alpha treatment. Respiration 2010, 80(3):212-219.
47. Leigh H., Kramer S.I. The psychiatric manifestations of endocrine disease. Adv Intern Med 1984, 29:413-445.
48. Constant E.L., Adam S., Seron X., et al. Anxiety and depression, attention, and executive functions in hypothyroidism. JInt Neuropsychol Soc 2005, 11(5):535-544.
49. Knopman D.S., Petersen R.C., Cha R.H., et al. Incidence and causes of nondegenerative nonvascular dementia: a population-based study. Arch Neurol 2006, 63(2):218-221.
50. Haupt M., Kurz A. Reversibility of dementia in hypothyroidism. JNeurol 1993, 240(6):333-335.
51. Nickel S.N., Frame B. Neurologic manifestations of myxedema. Neurology 1958, 8(7):511-517.
52. Stern R.A., Robinson B., Thorner A.R., et al. Asurvey study of neuropsychiatric complaints in patients with Graves' disease. JNeuropsychiatry Clin Neurosci 1996, 8(2):181-185.
53. Martin F.I., Deam D.R. Hyperthyroidism in elderly hospitalised patients. Clinical features and treatment outcomes. Med J Aust 1996, 164(4):200-203.
54. Duyff R.F., Van den Bosch J., Laman D.M., et al. Neuromuscular findings in thyroid dysfunction: a prospective clinical and electrodiagnostic study. JNeurol Neurosurg Psychiatr 2000, 68(6):750-755.
55. Song T.J., Kim S.J., Kim G.S., et al. The prevalence of thyrotoxicosis-related seizures. Thyroid 2010, 20(9):955-958.
56. Sahni V., Gupta N., Anuradha S., et al. Thyrotoxic neuropathy- an under diagnosed condition. Med J Malaysia 2007, 62(1):76-77.
57. Pereira A.M., Tiemensma J., Romijn J.A. Neuropsychiatric disorders in Cushing's syndrome. Neuroendocrinology 2010, 92(Suppl 1):65-70.
58. Kelly W.F., Kelly M.J., Faragher B. Aprospective study of psychiatric and psychological aspects of Cushing's syndrome. Clin Endocrinol (Oxf) 1996, 45(6):715-720.
59. Starkman M.N., Schteingart D.E., Schork M.A. Depressed mood and other psychiatric manifestations of Cushing's syndrome: relationship to hormone levels. Psychosom Med 1981, 43(1):3-18.
60. Kelly W.F. Psychiatric aspects of Cushing's syndrome. QJM 1996, 89(7):543-551.
61. Starkman M.N. Neuropsychiatric findings in Cushing syndrome and exogenous glucocorticoid administration. Endocrinol Metab Clin North Am 2013, 42(3):477-488.
62. Sharma S.T., Nieman L.K. Cushing's syndrome: all variants, detection, and treatment. Endocrinol Metab Clin North Am 2011, 40(2):379-391. viii-ix.
63. Heald A.H., Ghosh S., Bray S., et al. Long-term negative impact on quality of life in patients with successfully treated Cushing's disease. Clin Endocrinol (Oxf) 2004, 61(4):458-465.
64. Gotch P.M. Cushing's syndrome from the patient's perspective. Endocrinol Metab Clin North Am 1994, 23(3):607-617.
65. Charmandari E., Nicolaides N.C., Chrousos G.P. Adrenal insufficiency. Lancet 2014, pii:S0140-6736(13)61684-0. 10.1016/S0140-6736(13)61684-0.
66. Smith C.K., Barish J., Correa J., et al. Psychiatric disturbance in endocrinologic disease. Psychosom Med 1972, 34(1):69-86.
67. Hahner S., Loeffler M., Fassnacht M., et al. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. JClin Endocrinol Metab 2007, 92(10):3912-3922.
68. Victor M., Adams R.D., Collins G.H. The Wernicke-Korsakoff syndrome. A clinical and pathological study of 245 patients, 82 with post-mortem examinations. Contemp Neurol Ser 1971, 7:1-206.
69. Lachner C., Steinle N.I., Regenold W.T. The neuropsychiatry of vitamin B12 deficiency in elderly patients. JNeuropsychiatry Clin Neurosci 2012, 24(1):5-15.
70. Stabler S., Allen R. Cecil textbook of medicine 2004, 1054-1055. Saunders, Philadelphia.
71. Healton E.B., Savage D.G., Brust J.C., et al. Neurologic aspects of cobalamin deficiency. Medicine (Baltimore) 1991, 70(4):229-245.
72. Maiti A., Chatterjee S. Neuropsychiatric manifestations and their outcomes in chronic hypocalcaemia. JIndian Med Assoc 2013, 111(3):174-177.
73. Tracy J.A., Dyck P.J. Porphyria and its neurologic manifestations. Handb Clin Neurol 2014, 120:839-849.
74. Simon N.G., Herkes G.K. The neurologic manifestations of the acute porphyrias. JClin Neurosci 2011, 18(9):1147-1153.
75. Crimlisk H.L. The little imitator-porphyria: a neuropsychiatric disorder. JNeurol Neurosurg Psychiatr 1997, 62(4):319-328.
76. Walterfang M., Bonnot O., Mocellin R., et al. The neuropsychiatry of inborn errors of metabolism. JInherit Metab Dis 2013, 36(4):687-702.
77. Anderson K.E., Bloomer J.R., Bonkovsky H.L., et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 2005, 142(6):439-450.
78. Balwani M., Desnick R.J. The porphyrias: advances in diagnosis and treatment. Blood 2012, 120(23):4496-4504.
79. Brewer G.J., Yuzbasiyan-Gurkan V. Wilson disease. Medicine (Baltimore) 1992, 71(3):139-164.
80. Wiebers D.O., Hollenhorst R.W., Goldstein N.P. The ophthalmologic manifestations of Wilson's disease. Mayo Clin Proc 1977, 52(7):409-416.
81. Lorincz M.T. Recognition and treatment of neurologic Wilson's disease. Semin Neurol 2012, 32(5):538-543.
82. Darnell R.B., Posner J.B. Paraneoplastic syndromes affecting the nervous system. Semin Oncol 2006, 33(3):270-298.
83. Tüzün E., Dalmau J. Limbic encephalitis and variants: classification, diagnosis and treatment. Neurologist 2007, 13(5):261-271.
84. Kayser M.S., Kohler C.G., Dalmau J. Psychiatric manifestations of paraneoplastic disorders. Am J Psychiatry 2010, 167(9):1039-1050.